Dexamethasone
- Generic Name
- Dexamethasone
- Brand Names
- Baycadron, Ciprodex, Decadron, Dexamethasone Intensol, Dextenza, Dioptrol, Hexadrol, Hidex 6-day Taper, Maxidex, Maxitrol, Neofordex, Ozurdex, Taperdex 12 Day Taper, Taperdex 6 Day Taper, Taperdex 7-day Taper, Tobradex, Zcort 7 Day Taper
- Drug Type
- Small Molecule
- Chemical Formula
- C22H29FO5
- CAS Number
- 50-02-2
- Unique Ingredient Identifier
- 7S5I7G3JQL
- Background
Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like hydrocortisone and prednisolone.
Dexamethasone was granted FDA approval on 30 October 1958. In a press release for the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial on 16 June 2020, dexamethasone was recommended for use in COVID-19 patients with severe respiratory symptoms. Dexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen.
- Indication
Dexamethasone and ciprofloxacin otic suspension is indicated for bacterial infections with inflammation in acute otitis media and acute otitis externa. Intramuscular and intravenous injections are indicated for a number of endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Oral tablets are indicated for the treatment of multiple myeloma. An intravitreal implant is indicated for some forms of macular edema and non-infectious posterior uveitis affecting the posterior of the eye. Various ophthalmic formulations are indicated for inflammatory conditions of the eye.
- Associated Conditions
- Acute Gouty Arthritis, Acute Leukemia, Acute Otitis Externa, Acute Otitis Media (AOM), Adrenocortical Hyperfunction, Adrenocortical Insufficiency, Allergic Conjunctivitis (AC), Alopecia Areata (AA), Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Berylliosis, Bullous dermatitis herpetiformis, Bursitis, Chorioretinitis, Choroiditis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Conjunctivitis, Contact Dermatitis, Cushing's Syndrome, Dermatitis, Diabetic Macular Edema (DME), Discoid Lupus Erythematosus (DLE), Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Episcleritis, Erythroblastopenia, Eye Infections, Eye allergy, Glaucoma, Hypercalcemia, Immune Thrombocytopenia (ITP), Infection, Inflammation, Inflammation of the External Auditory Canal, Intraocular Inflammation, Iridocyclitis, Iritis, Keloids Scars, Keratitis, Lichen Planus (LP), Lichen simplex chronicus, Loeffler's syndrome, Lymphoma, Macular Edema, Meningitis caused by Mycobacterium Tuberculosis, Middle ear inflammation, Mucosal Inflammation of the eye, Multiple Myeloma (MM), Muscle Inflammation caused by Cataract Surgery of the eye, Mycosis Fungoides (MF), Necrobiosis lipoidica diabeticorum, Non-infectious Posterior Uveitis, Ocular Infections, Irritations and Inflammations, Ocular Inflammation, Ocular Inflammation and Pain, Ocular Irritation, Ocular Itching, Ophthalmia, Sympathetic, Optic Neuritis, Otitis Externa, Pemphigus, Perennial Allergic Rhinitis (PAR), Phlyctenular keratoconjunctivitis, Postoperative Infections of the eyes caused by susceptible bacteria, Posttraumatic Osteoarthritis, Regional Enteritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Rosacea, Sarcoidosis, Scleritis, Seasonal Allergic Rhinitis, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Stevens-Johnson Syndrome, Synovitis, Systemic Lupus Erythematosus, Tenosynovitis, Trichinosis, Tuberculosis (TB), Ulcerative Colitis, Uveitis, Vernal Keratoconjunctivitis, Acquired immune hemolytic anemia, Acute rheumatic carditis, Anterior eye segment inflammation, Corticosteroid-responsive dermatoses, Ear infection-not otherwise specified caused by susceptible bacteria, Exfoliative erythroderma, Granuloma annulare lesions, Non-suppurative Thyroiditis, Ocular bacterial infections, Severe Psoriasis, Steroid-responsive inflammation of the eye, Swelling of the eyes, Varicella-zoster virus acute retinal necrosis, Watery itchy eyes
- Associated Therapies
- -
Dexamethasone Study: Impact on Quality of Life of Continuing Dexamethasone Following Emetogenic Chemotherapy
- First Posted Date
- 2005-09-09
- Last Posted Date
- 2012-06-28
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 86
- Registration Number
- NCT00152867
- Locations
- 🇨🇦
Mount SinaiHospital, Toronto, Ontario, Canada
🇨🇦Princess Margaret Hospital, Toronto, Ontario, Canada
Dexamethasone Versus Methylprednisolone for the Treatment of Active Inflammatory Bowel Disease
- Conditions
- First Posted Date
- 2005-09-09
- Last Posted Date
- 2013-09-05
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 40
- Registration Number
- NCT00152620
- Locations
- 🇺🇸
University of Chicago Comer Children's Hospital, Chicago, Illinois, United States
Specific Effects of Escitalopram on Neuroendocrine Response
- Conditions
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2009-02-05
- Lead Sponsor
- Queen's University
- Target Recruit Count
- 8
- Registration Number
- NCT00150527
- Locations
- 🇨🇦
Providence Centre, Mental Health Services, Kingston, Ontario, Canada
Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies
- Conditions
- Interventions
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2017-05-02
- Lead Sponsor
- Amgen
- Target Recruit Count
- 48
- Registration Number
- NCT00150462
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
🇺🇸Tower Cancer Research Foundation, Beverly Hills, California, United States
Phase II Study of Velcade, Decadron, and Doxil Followed by Cyclophosphamide in Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2005-09-07
- Last Posted Date
- 2017-07-18
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 38
- Registration Number
- NCT00148317
- Locations
- 🇺🇸
Weill Medical College of Cornell University, New York, New York, United States
Study of Bortezomib (Velcade) in Combination With Dexamethasone to Treat Patients With Relapsed Hodgkin's Lymphoma
- Conditions
- First Posted Date
- 2005-09-07
- Last Posted Date
- 2008-07-10
- Lead Sponsor
- University of Cologne
- Target Recruit Count
- 37
- Registration Number
- NCT00148018
- Locations
- 🇩🇪
University of Cologne, Cologne, NRW, Germany
Liposomal Vincristine Plus Dexamethasone in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2005-09-05
- Last Posted Date
- 2019-12-12
- Lead Sponsor
- Acrotech Biopharma Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT00144963
- Locations
- 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States
R-ICE Versus R-DHAP in Patients Aged 18-65 With Relapse Diffuse Large B-cell Lymphoma
- First Posted Date
- 2005-08-30
- Last Posted Date
- 2019-08-28
- Lead Sponsor
- Lymphoma Study Association
- Target Recruit Count
- 481
- Registration Number
- NCT00137995
- Locations
- 🇮🇱
Israel Society of Hematology, Tel-Hashomer, Israel
🇨🇭Schweirische Arbeitsgruppe fur klinische Krebsforschung, Lausanne, Switzerland
🇫🇮Hospital district of south west Finland, Turku, Finland
A Study in Adults With Untreated Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2005-08-29
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 100
- Registration Number
- NCT00136435
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇨🇦Manitoba Blood & Marrow Transplant Program CancerCare Manitoba, Winnipeg, Manitoba, Canada
Study of Combination Therapy With VELCADE, Doxil, and Dexamethasone (VDd) in Multiple Myeloma
- Conditions
- First Posted Date
- 2005-08-25
- Last Posted Date
- 2012-02-07
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT00135187
- Locations
- 🇺🇸
University of Michigan Cancer Center, Ann Arbor, Michigan, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.